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Abstract
Background: Casein-free, gluten-free diets have been reported to mitigate some of the inflammatory gastrointestinal
and behavioral traits associated with autism, but the mechanism for this palliative effect has not been elucidated. We
recently showed that the opioid peptide beta-casomorphin-7, derived from bovine (bBCM7) milk, decreases cysteine
uptake, lowers levels of the antioxidant glutathione (GSH) and decreases the methyl donor S-adenosylmethionine
(SAM) in both Caco-2 human GI epithelial cells and SH-SY5Y human neuroblastoma cells. While human breast milk
can also release a similar peptide (hBCM-7), the bBCM7 and hBCM-7 vary greatly in potency; as the bBCM-7 is highly
potent and similar to morphine in it's effects. Since SAM is required for DNA methylation, we wanted to further
investigate the epigenetic effects of these food-derived opioid peptides. In the current study the main objective was
to characterize functional pathways and key genes responding to DNA methylation effects of food-derived opioid
peptides.
Methods: SH-SY5Y neuroblastoma cells were treated with 1 μM hBCM7 and bBCM7 and RNA and DNA were isolated
after 4 h with or without treatment. Transcriptional changes were assessed using a microarray approach and CpG
methylation status was analyzed at 450,000 CpG sites. Functional implications from both endpoints were evaluated via
Ingenuity Pathway Analysis 4.0 and KEGG pathway analysis was performed to identify biological interactions between
transcripts that were significantly altered at DNA methylation or transcriptional levels (p < 0.05, FDR <0.1).
Results: Here we show that hBCM7 and bBCM7, as well as morphine, cause epigenetic changes affecting gene
pathways related to gastrointestinal disease and inflammation. These epigenetic consequences exhibited the same
potency order as opiate inhibition of cysteine uptake insofar as hBCM7 was less potent than bBCM7, which was less
potent than morphine.
Conclusion: Our findings indicate that epigenetic effects of milk-derived opiate peptides may contribute to GI
dysfunction and inflammation in sensitive individuals. While the current study was performed using SH-SY5Y
neuronal cellular models, similar actions on other cells types might combine to cause symptoms of intolerance. These
actions may provide a potential contributing mechanism for the beneficial effects of a casein-free diet in alleviating
gastrointestinal symptoms in neurological conditions including autism and other conditions. Lastly, our study also
contributes to the evolving awareness of a “gut-brain connection”.
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Background
During early development, human breast milk and
bovine milk-based formulas are the best and frequently
the only source of infant nutrition. Casein, a class of
proteins that makes up roughly 80 % of the protein
found in milk, is broken down during digestion into a
number of smaller peptides. One of these breakdown
products is the opioid-like peptide beta-casomorphin-7
(BCM7) [1, 2], and a structurally similar opioid-like pep-
tide is released during digestion of wheat-derived gluten
[3, 4]. Canonically, food-derived opioid peptides are re-
ported to act on the μ-opioid receptor (μ-OR) and they
are able to reach the bloodstream [5] and cerebrospinal
fluid [6] with the potential to exert effects in the brain [7].
However, the downstream effects of this food-derived opi-
oid peptide exposure, especially in terms of gene expres-
sion and regulation, are still largely unknown. Beta-casein
variants are of two major sub-types; namely A1 and A2
type of beta-casein. It is noteworthy to mention that
BCM-7, the opioid peptide is only derived from A1-type
of beta-casein and not A2 upon digestion.
We recently showed that casein and gluten-derived
opioid peptides decrease excitatory amino acid trans-
porter 3 (EAAT3)-mediated cysteine uptake by human
GI epithelial cells and human neuronal cells in a dose-
dependent manner, resulting in redox and epigenetic
consequences via their capacity for μ-OR activation [8].
Epigenetic regulation of gene expression is of particular
importance during early development when changes in
DNA or histone methylation status can exert lifelong
and even transgenerational effects [9–11]. Thus milk-
derived opioid peptides may exert an important epigenetic
influence with extended consequences. It is noteworthy to
mention that the human form of BCM-7 was far less po-
tent as compared to the bovine form of BCM-7 in inhib-
ition of cysteine uptake, inducing oxidative stress as well
as decreased SAM levels.
With regard to neural development, epigenetic regula-
tion can influence neural stem cell differentiation as well
as neuronal plasticity and/or neuronal maturation, which
are particularly prominent during fetal and early postnatal
development [12]. We previously highlighted the critical
role of prenatal and postnatal epigenetic programming in
the redox-based linkage between GI, brain, and immune
systems, which could potentially contribute to the etiology
of autism and other disorders [10]. These redox-based
metabolic and epigenetic changes have not only been
identified in early developmental and neurological
diseases [13–15], but also characterized in diseases
arising across the lifespan, including immunological
[10, 16] and neurodegenerative disorders [17–19].
A gluten-free (GF) casein-free (CF) diet has been re-
ported to improve intestinal, autoimmune and neurological
symptoms in celiac disease [20, 21], autism [22] and
schizophrenia [23, 24]. However, the mechanism by which
a GF/CF diet improves these symptoms is not fully
understood, and in the absence of definitive evidence, the
potential benefit of these dietary interventions remains un-
explained or considered to be poor [25]. In the current
study we investigated the functional effects of milk-derived
opioid peptides using pathway analysis of genome wide
changes in global DNA methylation patterns, measured via
methyl-CpG binding domain (MBD) protein-enriched
genome sequencing (MBD-seq) in cultured human neuro-
blastoma cells, as well as changes in transcription status
using a genome-wide microarray expression assay. The ob-
served changes may contribute to adverse effects of milk-
derived opioid peptides in sensitive individuals.
Methods
Materials
Morphine was obtained from Sigma Chemicals (Catalog#
M8777, St. Louis, MO). Human and bovine forms of
BCM-7 were custom synthesized by Neopeptide
(Cambridge, MA).
Cell culture
SH-SY5Y human neuroblastoma cells were purchased
from ATCC® (Manassas, VA). Cells were grown as prolif-
erative monolayers in 10 cm standard tissue culture
dishes, containing 10 mL of alpha-modified Minimum
Essential Medium (α-MEM) from Mediatech (Manassas,
VA) supplemented with 1 % penicillin-streptomycin-
fungizone, also from Mediatech, and 10 % fetal bovine
serum (FBS) from HyClone (Logan, UT) at 37 °C with
5 % CO2. Cells (Passage # 4) treated for 4 h with 1 μM
hBCM7, bBCM7, morphine or left untreated as a control
prior to RNA or DNA extraction. This concentration
was chosen on the basis of previous dose–response stud-
ies indicating that 1 μM produced maximum inhibition
of EAAT3-mediated cysteine uptake.
DNA isolation
DNA from cell culture for the analysis of DNA methyla-
tion was isolated using the FitAmp™ Blood & Cultured
Cell DNA Extraction Kit from Epigentek (Farmingdale,
NY). Isolated DNA was quantified using a ND-1000
NanoDrop (Wilmington, DE) spectrophotometer.
RNA isolation
RNA from cell culture for the analysis of RNA transcription
was isolated using the RNAqueous®-4PCR kit from Ambion
(Austin, TX). Isolated RNA was treated with DNase,
followed by RNA quantification using a ND-1000
NanoDrop spectrophotometer.
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Site-specific CpG methylation: fragmentation and
MBD-capture
Genomic DNA was extracted from samples with the
Easy DNA kit (Invitrogen K1800-01; Grand Island,
NY) using the appropriate protocol for cell lines. DNA
methylation measurement was performed using the
MethylCap-Seq protocol, as described by De Meyer [26].
We used EdgeR, developed by Robinson et al. [27], for the
detection of regions with differential MBD coverage be-
tween conditions. The technical and biological variation
has to be estimated and modelled, while considering the
discrete nature of the count values. The EdgeR package
provides functions to estimate the biological variability
from low number of replicates and models the count data
using negative binomial distribution. We used a common
dispersion estimate to obtain Differential promoter
methylation test p-values. The region was called “differen-
tially methylated” if the FDR adjusted p-value (i.e. q-value)
was less than 0.10.
Microarray assays
For microarray hybridizations, 500 ng of total RNA
from each sample was labeled with fluorescent dye
(Cy3; Amersham Biosciences Corp, Piscataway, NJ)
using the Low RNA Input Linear Amplification Label-
ing kit (Agilent Technologies, Palo Alto, CA) following
the manufacturer’s protocol. The amount and quality
of the fluorescently labeled cRNA was assessed using a
NanoDrop ND-1000 spectrophotometer and an Agilent
Bioanalyzer. According to manufacturer’s specifications,
1.6 mg of Cy3-labeled cRNA was hybridized to the Agilent
Human Whole Genome Oligo Microarray (Agilent
Technologies, Inc., Palo Alto, CA) for 17 h, prior to
washing and scanning. Data was extracted from
scanned images using Feature Extraction Software
(Agilent Technologies, Inc., Palo Alto, CA).
Gene ontology and pathway analysis
Pairwise comparisons (e.g. hBCM-7 [4 h] vs bBCM-7
[4 h]) were carried out using Student’s t-test (at a fold
change ≥ 1.5, raw p ≤ 0.05; the N values in this pilot
study were small such that applying a Benjamini &
Hochberg FDR correction resulted in no DETs for the
hBCM-7 and bBCM-7 versus control comparisons) to
generate lists of differentially expressed genes. For each
comparison between treatments, individual lists of dif-
ferentially expressed (and differentially methylated)
genes were uploaded to the Ingenuity® Pathway Analysis
(IPA) program (http://www.ingenuity.com) for determin-
ation of biologically relevant functional categories (gene
ontologies) and canonical pathway involvement. The sig-
nificance value associated with Functional Analysis for a
dataset is a measure of the likelihood that the association
between a set of Functional Analysis molecules in these
data and a given process or pathway is due to random
chance. The p-value is calculated using the right-tailed
Fisher Exact Test. In general, p-values less than 0.05 indi-
cate a statistically significant, non-random association.
Hierarchical clustering
Clustering of samples was performed using the Euclidean
metric and data where each variable has been normalized
to mean = 0 and variance = 1, using linkage criteria set to
‘average linkage’. The resulting heat maps display the top
50 differentially-expressed transcripts compared to pooled
RNA from control cells (p ≤ 0.001). The list of probes is
found in Additional file 1: Table S1.
Statistical analysis
Statistical analyses were carried out using Graph Pad
Prism® version 5.01. Student’s t-test for independent
means was used to test for significant differences be-
tween untreated control and experimental groups. Data
were expressed as mean ± standard error of the mean
(SEM). Comparisons between multiple groups of data
were conducted using one-way analysis of variance
(ANOVA) followed by Tukey’s post-hoc test was used to
determine the differences between individual groups.
Results
Our previous results reported global DNA methylation
changes under the influence of opioid peptides. However,
the hBCM-7 was far less potent as compared to the bo-
vine form of BCM-7 in altering the global DNA methyla-
tion status as well as changes in GSH and SAM levels [9].
In the current study, we investigated the genome-wide
epigenetic changes under the influence of these opioid
peptides. To investigate functional pathway and gene net-
work changes induced by hBCM7, bBCM7 and morphine,
the DNA methylation MBD-seq and DNA microarray
data were collected. For this purpose, control SH-SY5Y
neuroblastoma cells and cells treated for 4 h with 1 μM
hBCM7, bBCM7 or morphine were used, the latter serv-
ing as a positive opioid effect control. The dose and time-
points were selected based on our previous studies [8].
Whole genome DNA MBD-seq revealed differentially
methylated promoter transcripts (DMTs), as defined by
FDR < 0.1 and microarray data revealed differentially
expressed transcripts (DETs), defined by fold change ≥ 1.5
and raw p-value ≤ 0.05, which included differentially meth-
ylated/ transcribed genes from both genic and non-coding
regions.
Treatment with the prototypical opiod morphine
(positive control) resulted in 4950 DETs, while bBCM7
treatment yielded 1467 and hBCM7 treatment resulted
in 581; hence the rank order in gene expression changes
was morphine > bBCM7 > hBCM7 (Fig. 1). Morphine
treatment resulted in a distinct bias towards gene up-
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regulation, with 4785/4950 DETs (96.7 %) reflecting in-
creased expression, while for bBCM7 1259/1467 (85.8 %) of
DETs were associated with increased expression. By con-
trast, only 209/581 DETs (36.0 %) for hBCM7 treatment
reflected up-regulation.
Next, about 501 DETs were shared by both morphine
and bBCM7, 178 overlapped between morphine and
hBCM7, 76 overlapped between hBCM7 and bBCM7,
while 33 overlapped between all three treatments.
Morphine and bBCM7 shared a higher number of DETs,
as compared to morphine and hBCM7 (Fig. 1). Hierarchical
clustering for top 50 DETs showed that changes in gene ex-
pression for hBCM7 and bBCM7 are more related to each
other than to morphine (Fig. 2).
Morphine treatment resulted in 3673 promoter region
DMTs (defined as transcription start site ± 500 bp),
bBCM7~ 197 and hBCM7~ 346 DMTs; with the rank for
differential promoter region methylation as morphine >
hBCM7 > bBCM7. Of these DMTs, morphine and bBCM7
shared 159, morphine and hBCM7 had 25 common and
only 1 DMTs overlapped between all three treatments
(Fig. 1).
Next, promoter region methylation of all 53,561 genes
was evaluated at their transcription start sites (TSS) and
relative DNA methylation was calculated for 1000 bp in
either direction, normalized to the level at the control at
TSS. A fluctuating methylation density was observed in
the TSS region in untreated control cells, featuring a
peak of increased methylation at +65 to +80, flanked by
two valleys of decreased methylation at −200 to −300
and +600 to +800 bp (Fig. 3). While the overall pattern
of TSS DNA methylation was unchanged, a 4 h opioid
treatment increased genome-wide TSS methylation.
Morphine caused a 22 % increase in DNA methylation
above the control level at the + 65 to +80 peak, followed
by bBCM7 (17 %) and hBCM7 (11 %); (Inset in Fig. 3).
The relative efficacy of these opioids to alter DNA
promoter methylation mirrors their efficacy in their in-
hibition of cysteine uptake as previously reported by this
lab, which also had an efficacy order of morphine >
bBCM7 > hBCM7 [28]. Thus bBCM7 exhibits a higher
efficacy for increasing TSS methylation than hBCM7
(p < 0.05).
Using ingenuity pathway analysis (IPA), we examined
the biological interactions between genes and noncoding
mRNAs, which changed in either their promoter region
methylation status or their transcription levels upon ex-
posure to hBCM7, bBCM7 or morphine. The functional
biological pathways most significantly populated with el-
ements from these lists were identified (Additional file 1:
Table S2). Among the diseases and disorders that were
found to be significantly associated with the observed
DETs and DMTs, three diseases or disorders of particular
interest were identified: gastrointestinal disease,
Fig. 1 Venn diagrams representing overlap in DETs and DMTs between treatment conditions. SH-SY5Y human neuroblastoma cells were treated with
1 μM morphine, bBCM7 or hBCM7 for 4 h (n= 5). Gene expression was analyzed by genome-wide microarray to generate lists of differentially expressed
transcripts (DETs; Panel a and DNA methylation was analyzed by MBD-seq to yield lists of differentially methylated transcripts (DMTs; Panel b DMTs and
DETs were plotted to illustrate overlapping transcript changes caused by one or more of the treatment groups compared with non-treated control. For
DETs, N= 3; fold change≥ 1.5; raw p≤ 0.05. For DMTs, N= 5, FDR < 0.1
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inflammatory disease and inflammatory response (Table 1).
Morphine-induced DMTs were associated with
gastrointestinal disease and inflammatory response, while
morphine induced DETs were associated with inflamma-
tory disease and response. hBCM7-induced DMTs were
associated with gastrointestinal disease, and bBCM7
DMTs were associated with inflammatory disease.
Lastly, we investigated if there were any underlying
opioid-mediated changes in the epigenetic status of
enzymes and proteins involved in the transulfuration and
glutathione synthesis pathway. We observed differences in
DNA methylation levels of several genes from the transsul-
furation pathway and the methionine cycle (Fig. 4). Both
genic and intragenic methylation changes were observed.
More importantly these changes observed in the epigenetic
patterns were also correlated the gene expression changes
we reported in our previous studies. For example, mor-
phine and bBCM7 both induced elevated levels in the
DNA methylation patterns in the promoter region of the
gene coding for the excitatory amino acid transporter
Fig. 2 Differential gene expression in SH-SY5Y human neuroblastoma cells treated with morphine, bBCM7 or hBCM7. Gene expression data were
obtained using Agilent Human Whole Genome Oligo Microarray. The heat map represents the top 50 differentially expressed probes compared
to control (p < 0.001). Each column represents a single treatment and each row represents a single gene. At the top of the diagram is a dendogram
that displays the relatedness of the individual samples
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(EAAT3). This corresponded with our previous results
wherein we reported that morphine and bBCM7 treatment
was associated with decreased levels of EAAT3 transporter
as measured using qPCR [8]. Similar association between
changes in mRNA levels and the DNA methylation levels
were also observed with other enzymes and proteins in-
volved in the transulfuration pathway [8]. Thus, morphine,
hBCM7 and bBCM7 produce changes in DNA
methylation, which may affect metabolic pathways regulat-
ing GSH and SAM levels.
Discussion
Epigenetic regulation not only allows a pluripotent cell
to differentiate into alternative cell types containing the
same genetic information, but it also provides a mechan-
ism for plastic and adaptive responses to changes in the
Fig. 3 Methylation profiles in control and treated cells. SH-SY5Y human neuroblastoma cells were treated with 1 μM morphine, bBCM7 or hBCM7
for 4 h (n = 5) and DNA methylation was analyzed by MBD-seq. 53,561 genes were aligned at their transcription start site (TSS) and average
methylation between -3000 bp and +3000 bp was computed and normalized to values at -3000 bp
Table 1 SH-SY5Y human neuroblastoma cells were treated with 1 μM morphine, bBCM7 or hBCM7 for 4 h (n = 5). DNA methylation
was measured by MBD-seq, while mRNA transcription was measured with whole genome microarray. IPA functional analysis was
performed with DETs and DMTs for the treatments vs. control. P values were generated by IPA for gene ontology categories associ-
ated with gastrointestinal disease, inflammatory disease or inflammatory response for each treatment vs. control. P-values are dis-
played as a range based on the number of genes from the experimental list that appears in a particular ontology [sub-group] within
a Disease or Disorder category
Disease or disorder P-value ranges for DMTs
Morphine hBCM7 bBCM7
Gastrointestinal disease 9.34E-08 – 1.07E-02 1.09E-12 – 7.32E-03
Inflammatory disease 3.96E-03 – 4.51E-02
Inflammatory response 5.46E-05 – 1.07E-02
P-value ranges for DETs
Morphine hBCM7 bBCM7
Gastrointestinal disease
Inflammatory disease 1.33E-12 – 1.35E-03
Inflammatory response 4.06E-08 – 1.33E-03
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cellular environment arising from physiological
substances, xenobiotics, or food, representing a form of
genetic metadata. We previously outlined a possible
metabolic link between redox and methylation, and a
potential mechanism by which changes in redox status
translate into epigenetic outcomes [14, 19] and lastly, the
potential for nutritional factors to affect prenatal and
postnatal epigenetic programming [10]. Redox and
epigenetic changes have been implicated in early devel-
opmental and neurological diseases [13–15], as well as
immunological [10, 16] and neurodegenerative disorders
[17–19]. Recently, we showed that redox effects of food-
derived peptides with opioid activity exert powerful
control over DNA methylation [8]; however, a synthetic
Fig. 4 DNA-methylation distribution of genes involved in transsulfuration pathway. Gene-specific graphical representation of distribution of
methylation peaks for the genes involved in the transsulfuration pathway. The Refseq genes are shown in orange / blue color. The CpG density
for the specific region of the gene is also indicated. Reference genome is from the H2G2 genome browser which uses the hg19 version of the
human genome
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peptide constituted with a scrambled sequence of the
BCM7, did not show any effect on the global DNA
methylation (Additional file 2: Figure S3), acting as a
negative control, not activating the mu opioid receptor
and inducing downstream epigenetic changes. Thus, the
current results are an extension and insightful investiga-
tion of our previous work, clarifying the epigenetic ef-
fects of food-derived opioids, especially milk-derived
opioids.
Using SH-SY5Y human neuroblastoma cells, we found
that bBCM7 and hBCM7, as well as the prototypical
opiate agonist morphine, caused epigenetic as well as tran-
scriptional changes that could be linked to pathways con-
tributing to gastrointestinal disease and inflammation in
the GI tract. Although, it is noteworthy to mention that
the bBCM-7 released from A1-type of beta casein was far
more potent in inducing these epigenetic changes as com-
pared to the hBCM-7. It should be noted that the primary
endpoint for the current study was not to model GI dis-
eases in SH-SY5Y cells, but it is highly intriguing that the
pathway analysis identified GI function and diseases to be
the most highly affected. This result may not be surprising
since we have previously showed that EAAT3 is present at
high levels in human intestinal epithelial cells (Caco2
cells), and food-derived opioid peptides can inhibit
EAAT3-mediated cysteine uptake in these cells, resulting
in altered redox and methylation capacity [8]. Thus, these
molecular effects of opiates on antioxidant levels and
methylation status can occur in different cell types and
can result in overlapping epigenetic consequences.
Several previous studies have indicated the use of SH-
SY5Y cells as models for neuronal cells for research
related to central nervous system [8] as well as enteric
nervous system [29]. Furthermore, oxidative stress has
recently been recognized as a significant factor in the
pathogenesis of gastrointestinal complications [30], and
treatment with GSH or the GSH released from glial cells
resulted in alleviation of oxidative stress in neuronal
cells [29] as well as gastrointestinal symptoms. Mu-
opioid receptors are highly expressed in the gastro-
intestinal tract including in neurons of the enteric ner-
vous system. Hence, although we did not use SH-SY5Y as
a model for induction of gastrointestinal diseases, we ob-
served that induction of oxidative stress resulted in epi-
genetic changes which corresponded to gastrointestinal
diseases. These results provide a potential explanation for
the observed high prevalence of GI dysfunction co-
morbidity in patients with neurological disorders includ-
ing autism spectrum disorders.
Both wheat- and milk-derived opiate peptides inhibit
the uptake of cysteine, resulting in a decrease in GSH
synthesis [8]. This decrease in antioxidant capacity leads
to inhibition of the redox sensitive enzyme methionine
synthase and a decrease in the availability of the methyl
donor S-adenosylmethionine (SAM). Oxidative stress
and decreased levels of SAM and GSH have been associ-
ated with autism by multiple studies [31–41]. The
decrease in SAM translates into effects on global DNA
methylation, with epigenetic consequences, which can
contribute to neurological and neurodevelopmental dis-
orders such as autism [42–47].
The changes in DNA methylation and gene expression
we observed were associated with inflammation and
gastrointestinal disease-related metabolic pathways. One
way to interpret this result is a dysfunctional positive
feed-back loop in which food-derived opiate peptides
decrease cysteine uptake from the GI tract, causing in-
flammation and gastrointestinal disease which further
limits the ability to take up cysteine and other important
nutrients. Avoiding milk-derived BCM-7 might be bene-
ficial to prevent this inflammation in sensitive individ-
uals; however, supporting clinical evidence is not yet
reported and hence any clinical extrapolation of these in
vitro studies should be done with caution. In some, but
not all studies, dietary intervention with a gluten-free
casein-free diet has been shown to improve symptom
presentation in autistic subjects [22, 48, 49]. BCM7 has
been linked to delayed psychomotor development in in-
fants [50]. Interestingly, a genetic variant in dipeptidyl-
peptidase IV (DPP-IV), the enzyme responsible for
hydrolysis of BCM7, was found to be significantly over-
represented in autistic male subjects [51], and autoanti-
bodies against DPP-IV are found in autistic subjects
[52]. Thus diminished activity of DPP-IV may contribute
to increased activity of BCM7 in autism. Our findings
also highlight a difference in the efficacy of human vs.
bovine-derived BCM7 in altering DNA promoter methyla-
tion and mRNA transcription inflammation. The ability of
BCM7 to alter gene expression has been previously re-
ported [12]. Here we show that bBCM7 acts more like
morphine than hBCM7, in the both magnitude of DNA
promoter methylation changes, a similar bias toward
mRNA up-regulation and in the extent of overlapping
discrete DMTs and DETs. Thus the epigenetic effects of
bBCM7 may be quantitatively and qualitatively different
from those of hBCM7, which could potentially also provide
a molecular rationale for the recommendation of breast-
feeding vs. formula feeding during early development.
Conclusion
Results from the current study indicate that epigenetic
effects of milk-derived opiate, especially bovine BCM-7
peptides may possibly contribute to GI dysfunction and to
development of inflammation. Thus eliminating these opi-
oid peptides from the diet may reverse these effects in sen-
sitive individuals, although future clinical studies will be
required to further investigate this mechanism. While
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preliminary, our findings indicate a “gut-brain” epigenetic
relationship.
The data set supporting the results of this article are
included as additional files for supplementary Figure S1,
S2 and Additional file 2: Figure S3 on the journal
website.
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transcripts associated with the disease or disorder. (PDF 60.5 kb)
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